Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EBITDA (2016 - 2025)

Cytosorbents (CTSO) has disclosed EBITDA for 14 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 40.75% year-over-year to -$2.9 million, compared with a TTM value of -$14.1 million through Sep 2025, up 37.27%, and an annual FY2024 reading of -$16.8 million, up 47.46% over the prior year.
  • EBITDA was -$2.9 million for Q3 2025 at Cytosorbents, up from -$3.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.9 million in Q1 2021 and bottomed at -$9.6 million in Q4 2021.
  • Average EBITDA over 5 years is -$5.9 million, with a median of -$5.4 million recorded in 2021.
  • The sharpest move saw EBITDA plummeted 262.98% in 2021, then surged 60.37% in 2024.
  • Year by year, EBITDA stood at -$9.6 million in 2021, then soared by 33.52% to -$6.4 million in 2022, then crashed by 48.01% to -$9.4 million in 2023, then soared by 60.37% to -$3.7 million in 2024, then grew by 23.25% to -$2.9 million in 2025.
  • Business Quant data shows EBITDA for CTSO at -$2.9 million in Q3 2025, -$3.6 million in Q2 2025, and -$3.9 million in Q1 2025.